Articles

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment

Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA;Department of Medicine, University of California, San Francisco, CA
Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA;Department of Medicine, University of California, San Francisco, CA
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA;Department of Medicine, University of California, San Francisco, CA
Department of Laboratory Medicine, University of California, San Francisco, CA;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
Vol. 103 No. 7 (2018): July, 2018 https://doi.org/10.3324/haematol.2017.174482